Special Issue "Asymmetric Synthesis and Medicinal Chemistry"
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: closed (31 January 2010)
Prof. Dr. Oliver Reiser
Institut für Organische Chemie, Universität Regensburg, Universitätsstr. 31, 93053 Regensburg, Germany
Phone: +49 (0)941 943 4631(4630)
Fax: +49 (0)941 943 4121
Interests: asymmetric catalysis; stereoselective synthesis; natural product; synthesis; unnatural amino acids; foldamers
Any new drug that¹s chiral is likely to be developed and marketed as a single enantiomer. You win more than you lose with single enantiomers.
This statement from an article in Chem. Eng. News emphasized in 2003 the importance of enantiopure pharmaceuticals. Asymmetric Synthesis and Medicinal Chemistry are areas closely related to each other, and very often fundamental contributions in the development of new asymmetric processes initially disclosed on small scale are transfered in a most impressive way into industrial applications, showing the relevance of those fields for academia and industry alike.
I would like to invite contributions to this special issue of Pharamceuticals "Asymmetric Synthesis and Medicinal Chemistry" as an opportunity to showcase the creativity of leading scientists to tackle the challenges in the development of chiral drugs.
Prof. Dr. Oliver Reiser
All papers should be submitted to firstname.lastname@example.org. To be published continuously until the deadline and papers will be listed together at the special issue website.
Submitted papers should not have been published nor be under consideration for publication elsewhere. All papers are refereed through a peer-review process. A guide for authors is available on the Instructions for Authors page. Pharmaceuticals is a new international, peer-reviewed, quarterly open access journal published by MDPI.
Article Processing Charges (APC) for publication in this open access journal are waived for well-prepared manuscripts submitted by 30 June 2010. English correction or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those paper accepted for publication, that require extensive additional formatting and/or English corrections.
Pharmaceuticals 2010, 3(4), 1063-1069; doi:10.3390/ph3041063
Received: 21 December 2009; in revised form: 5 January 2010 / Accepted: 29 March 2010 / Published: 31 March 2010| Download PDF Full-text (207 KB)
Last update: 14 July 2009